Replimune Group, Inc.
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $0
- Net income
- -$247.3M
- Total assets
- $551.3M
- Market cap
- $782.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $261.6M
- Operating income
- -$261.6M
- Income tax
- $468.0K
- Net income
- -$247.3M
- EPS (basic)
- $-3.07
- EPS (diluted)
- $-3.07
Balance sheet
- Total assets
- $551.3M
- Current assets
- $495.9M
- Total liabilities
- $135.5M
- Current liabilities
- $62.4M
- Shareholders’ equity
- $415.8M
Cash flow
- Operating cash flow
- -$192.2M
- Investing cash flow
- -$23.8M
- Financing cash flow
- $252.4M
- Net cash flow
- $36.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $782.0M
- EPS (diluted)
- $-3.07
- Shares outstanding
- 87.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 20, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $247.3M in FY2018.
- Trading 29% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Replimune Group, Inc..
Write a review
News about Replimune Group, Inc.
News & sentiment via Polygon.io
